Updated

A federal appeals court ruled in favor of Gilead Sciences, blocking the sale of imported HIV drugs that competed with the company's branded products. The ruling protects Gilead's market position in its HIV treatment franchise. The decision is a notable legal win for Gilead as it continues to defend intellectual property and market exclusivity around its core drug portfolio.